Live Breaking News & Updates on J Bryan Iorgulescu

Stay updated with breaking news from J bryan iorgulescu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Personalized vaccine produces long-lasting anti-tumor response in patients with melanoma, study shows


Date Time
Personalized vaccine produces long-lasting anti-tumor response in patients with melanoma, study shows
Four years after patients with melanoma were treated with a personalized cancer vaccine, the immune response kindled by the vaccine remains robust and effective in keeping cancer cells under control, researchers at Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and the Broad Institute of MIT and Harvard report in a new study.
The findings, published online today by the journal Nature Medicine, demonstrate the staying power of the immune response generated by the vaccine, known as NeoVax, which works by targeting specific proteins on each patient’s tumor cells. The researchers found that, nearly four years after vaccination, the patients’ immune system cells were active not only against tumor cells with those distinctive proteins, but also spread to other proteins found in those patients’ tumor cells. ....

United States , Massachusetts Institute Of Technology , City Of , United Kingdom , Dana Farber Cancer Institute , Pavan Bachireddy , Robert Redd , Jason Pyrdol , Giacomo Oliveira , Charlesh Yoon , Adriennem Luoma , Patricka Ott , Anita Giobbie Hurder , Wandi Zhang , Danh Barouch , Zoe Ciantra , Catherinej Wu , Bradleyl Pentelute , Donna Neuberg , Kai Wucherpfennig , Rebecca Holden , Lauren Peter , Elizabethi Buchbinder , Satyen Gohil , Teddy Huang , Liudmilla Elagina ,

Vaccine produces long-lasting anti-tumor response in patients with melanoma


 E-Mail
BOSTON - Four years after patients with melanoma were treated with a personalized cancer vaccine, the immune response kindled by the vaccine remains robust and effective in keeping cancer cells under control, researchers at Dana-Farber Cancer Institute, Brigham and Women s Hospital, and the Broad Institute of MIT and Harvard report in a new study.
The findings, published online today by the journal
Nature Medicine, demonstrate the staying power of the immune response generated by the vaccine, known as NeoVax, which works by targeting specific proteins on each patient s tumor cells. The researchers found that, nearly four years after vaccination, the patients immune system cells were active not only against tumor cells with those distinctive proteins, but also spread to other proteins found in those patients tumor cells. ....

United States , Massachusetts Institute Of Technology , Dana Farber Cancer Institute , City Of , United Kingdom , Pavan Bachireddy , Robert Redd , Jason Pyrdol , Giacomo Oliveira , Charlesh Yoon , Adriennem Luoma , Patricka Ott , Anita Giobbie Hurder , Wandi Zhang , Danh Barouch , Zoe Ciantra , Catherinej Wu , Bradleyl Pentelute , Donna Neuberg , Kai Wucherpfennig , Rebecca Holden , Lauren Peter , Elizabethi Buchbinder , Satyen Gohil , Teddy Huang , Liudmilla Elagina ,